Coded tablets and test creams were kindly provided by A/S Dumex, Copenhagen.
A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea
Version of Record online: 29 JUL 2006
British Journal of Dermatology
Volume 109, Issue 1, pages 63–66, July 1983
How to Cite
NIELSEN, P.G. (1983), A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology, 109: 63–66. doi: 10.1111/j.1365-2133.1983.tb03993.x
- Issue online: 29 JUL 2006
- Version of Record online: 29 JUL 2006
- Accepted for publication 2 November 1982
In a randomized double-blind trial fifty-one patients with rosacea were treated for 2 months with either 1% metronidazole cream and placebo tablets or with 250 mg oxytetracycline tablets taken twice daily, and placebo cream (the cream base). The patients were assessed before and at the end of the trial, using the following criteria: (1) overall clinical assessment, (2) lesion counts, (3) degree of erythema, (4) independent photographic evaluation, (5) patients' opinion. An improvement was shown in 90% of the patients of both groups, and there was no significant difference between the two treatments.
One per cent metronidazole cream has been shown to be significantly better than a placebo cream in the treatment of rosacea (Gamborg Nielsen, 1983a), It was therefore considered important to compare the cream with conventional therapy, and for this reason a double-blind study of 1% metronidazole cream versus a daily dose of 500 mg oxytetracycline was performed.